ECS Botanics Holdings Ltd. advised that it has secured a one year, rolling supply agreement with Australian cannabis company, Canngea Pty Ltd. ("Canngea"). The agreement will generate a minimum of $410,000 in revenue and adds to the Company's growing revenue profile. Under the agreement and via ECS' existing Murray Meds licence, the Company will supply Canngea with a minimum of $410,000 in GMP manufactured medicinal cannabis products per year, including dry flower and oils. ECS expects first dispatch of product to occur in October this year. Both parties may terminate the agreement upon any material breach of this agreement that cannot be remedied within 20 business days of notice of that breach being given or upon insolvency or liquidation of either party. The agreement will automatically renew for a period of one year, unless a party gives not less than 60 days notice. ECS' significant production capacity, pricing and B2B model is enabling Australian cannabis companies to switch to ECS' local supply rather than relying on overseas imports, allowing ECS to grow through capturing existing market share as well as organic growth in patients numbers. Patient numbers are continuing grow as red tape is reduced, increased awareness and GP education and opening of more cannabis clinics.